Log In
BCIQ
Print this Print this
 

MI-519-64

  Manage Alerts
Collapse Summary General Information
Company Ascentage Pharma Group Corp. Ltd.
DescriptionSmall molecule inhibitor of p53-MDM2 protein-protein interactions
Molecular Target p53 ; Mdm2 p53 binding protein homolog (MDM2) (HDM2)
Mechanism of ActionMdm2 p53 binding protein homolog (MDM2) antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentDiscovery
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerSanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$398.0M

$8.0M

$390.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/07/2010

$398.0M

$8.0M

$390.0M

Get a free BioCentury trial today